Article ID Journal Published Year Pages File Type
3369190 Journal of Clinical Virology 2012 7 Pages PDF
Abstract

BackgroundRecent data suggest that subjects harbouring low-frequency variants of HIV that are resistant to non-nucleoside reverse-transcriptase inhibitors (NNRTI) could suffer virological failure when treated with NNRTI-based therapy. Rilpivirine, a second-generation NNRTI, will be used in first-line regimen therapy, but the prevalence of minority variants that are resistant to rilpivirine is unknown.ObjectivesWe evaluated the presence of low-frequency NNRTI resistance associated mutations (RAMs) in 27 patients with a primary HIV-1 infection.Study designWe performed genotypic resistance test at baseline and used ultradeep pyrosequencing (UDPS) to detect minority RAMs.ResultsBulk genotyping identified NNRTI-resistant RAMs in 3/27 (11%) patients while UDPS identified NNRTI-resistant RAMs in 10/27 (37%) patients. The 11 RAMs not detected by bulk sequencing were A98G (n = 2), L100I (n = 3), K101E (n = 2), V106I (n = 3) and E138G (n = 1). The prevalence of these minority variants was 0.34–18.26%. The absolute copy numbers of minority resistant variants were 3.21–5.53 log copies/mL. CRF02 harboured more minority resistant variants than subtypes B (P < 0.05). Four samples (15%) had a major rilpivirine resistant mutation (E138G, K101E and E138A), 3 of which were detected by UDPS.ConclusionIn these primary HIV infected patients, as regards to the detection of RAMs at the cut-off level > 15–25% of the virus population, the concordance between bulk genotypic and UDPS was perfect. UDPS detected additional major NNRTI-resistant mutations, including rilpivirine resistant variants. Further studies are needed to assess the impact of these minority variants on treatment efficacy.

Related Topics
Life Sciences Immunology and Microbiology Applied Microbiology and Biotechnology
Authors
, , , , , , , , ,